Engineering Asahi Kasei Completes Development of Second MCC Plant

Source: Press release Ahlam Rais 2 min Reading Time

Related Vendors

Asahi Kasei has successfully completed the construction of its second plant for Ceolus microcrystalline cellulose (MCC) in Japan. The new plant will increase the supply capacity of Ceolus MCC and aims to begin commercial production of each grade from April 2023.

The new plant is currently undergoing trial operation, with commercial production of each grade scheduled to begin in succession from April 2023.(Source:  Asahi Kasei)
The new plant is currently undergoing trial operation, with commercial production of each grade scheduled to begin in succession from April 2023.
(Source: Asahi Kasei)

Düsseldorf/Germany – Asahi Kasei has completed the construction of its second plant for Ceolus microcrystalline cellulose (MCC) at its Mizushima Works in Kurashiki, Okayama, Japan, in January 2023. With the new facility, the company underlines its commitment to meet the substantially growing demand for its MCC. The Functional Additives Division of Asahi Kasei’s Life Innovation SBU has manufactured Ceolus in Nobeoka, Miyazaki, Japan, since 1970.

Ceolus is supplied to customers around the world, primarily for use as tablet binder for pharmaceuticals. Demand for Ceolus used in pharmaceutical tablets is growing substantially, especially for the proprietary high-performance grades Ceolus KG and Ceolus UF. The second plant will not only raise supply capacity but also enhance the supply stability through production at multiple sites. The new plant is currently undergoing trial operation, with commercial production of each grade scheduled to begin in succession from April 2023.

Stay up to Date

Do you want the latest news, specialist articles and information on new products? Then you can register for our free newsletter:

Choose your Newsletter

“The increased capacity at this new plant will enable us to provide a more stable supply of Ceolus for distribution centers around the world to get products to customers in greater quantities,” says Eiichi Hori, Senior General Manager of Functional Additives Division. “The second plant will make Ceolus more accessible to patients around the world. We are excited to see the innovative, new formulations that pharmaceutical and supplement manufacturers will develop utilizing our MCC.”

Asahi Kasei expects that the new plant will make a further contribution to life and living for people around the world by providing Ceolus to more customers globally, enabling the manufacture of pharmaceuticals and supplements that have been difficult to make into tablets, and meeting the needs of pharmaceutical companies, supplement companies, and patients through the development of high-performance products.

(ID:49201632)

Subscribe to the newsletter now

Don't Miss out on Our Best Content

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy. The consent declaration relates, among other things, to the sending of editorial newsletters by email and to data matching for marketing purposes with selected advertising partners (e.g., LinkedIn, Google, Meta)

Unfold for details of your consent